* NextCure Inc is expected to show no change in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for NextCure Inc is for a loss of 34 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for NextCure Inc is $4.00, above its last closing price of $1.36.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.38 -0.38 -46
Jan. 1 0001 -0.46 -0.46 -32.5
Dec. 31 2023 -0.48 -0.54 4
Sep. 30 2023 -0.66 -0.66 22.4
Jan. -0.59 -0.59 -0.64 Missed -8.5
1 0001
Jan. 1 0001 -0.62 -0.62 -0.58 Beat 6.5
Jan. 1 0001 -0.65 -0.66 -0.62 Beat 5.5
Sep. 30 2022 -0.62 -0.63 -0.68 Missed -8.7
This summary was machine generated October 29 at 11:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。